Published in JAMA on February 10, 1969
A comparative field evaluation of three live, attenuated rubella virus vaccines. Am J Public Health (1971) 0.93
Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients. Immunogenetics (2014) 0.80
Viral infections in pregnancy. Yale J Biol Med (1969) 0.79
Attenuated rubella vaccine (HPV-77): evaluation in a large controlled trial. Am J Public Health (1971) 0.75
Infectious diseases: annual review of significant publications. Postgrad Med J (1970) 0.75
The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol (1987) 17.36
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet (1981) 13.54
Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. Am J Ophthalmol (1970) 10.68
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
New knowledge of chlamydiae and the diseases they cause. J Infect Dis (1975) 9.35
A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med (1986) 8.03
Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer (1988) 7.05
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med (1990) 6.94
Primary isolation of TRIC organisms in HeLa 229 cells treated with DEAE-dextran. J Infect Dis (1972) 6.85
Treatment of acute childhood diarrhea with homeopathic medicine: a randomized clinical trial in Nicaragua. Pediatrics (1994) 6.69
Human serology in Chlamydia trachomatis infection with microimmunofluorescence. J Infect Dis (1974) 6.18
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med (1975) 5.49
Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 5.30
Immunotyping of Chlamydia trachomatis with monoclonal antibodies. J Infect Dis (1985) 5.29
Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med (1982) 4.98
Chlamydia pneumoniae (TWAR). Clin Microbiol Rev (1995) 4.93
Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet (1987) 4.33
The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med (1990) 4.25
Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med (1996) 4.13
New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) (1990) 4.04
Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis (1993) 4.02
Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet (1983) 4.01
Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (1993) 3.91
Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis (2000) 3.73
Further classification of TRIC agents from ocular trachoma and other sources by the mouse toxicity prevention test. Am J Ophthalmol (1967) 3.63
Isolation of viruses, bacteria and other organisms from venereal disease clinic patients: methodology and problems associated with multiple isolations. Health Lab Sci (1973) 3.62
Functional dissection and sequence of yeast HAP1 activator. Cell (1989) 3.56
Outer membrane protein A of Escherichia coli contributes to invasion of brain microvascular endothelial cells. Infect Immun (1996) 3.53
Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis (1986) 3.50
The acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.49
Antimicrobial activity of several antibiotics and a sulfonamide against Chlamydia trachomatis organisms in cell culture. Antimicrob Agents Chemother (1977) 3.34
The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med (1992) 3.32
Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol (1997) 3.22
Mycobacterium. Bacteriol Rev (1977) 3.20
Purification and properties of staphylococcal delta hemolysin. Infect Immun (1971) 3.19
Identification of a new group of Chlamydia psittaci strains called TWAR. J Clin Microbiol (1986) 3.11
The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol (1977) 3.07
Simplified microimmunofluorescence test with trachoma-lymphogranuloma venereum (Chlamydia trachomatis) antigens for use as a screening test for antibody. J Clin Microbiol (1975) 3.03
T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol (1989) 3.00
Pneumonia associated with the TWAR strain of Chlamydia. Ann Intern Med (1987) 3.00
Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group. Pediatrics (1995) 2.98
Anaerobic degradation of toluene by a denitrifying bacterium. Appl Environ Microbiol (1991) 2.98
Invasion of brain microvascular endothelial cells by group B streptococci. Infect Immun (1997) 2.97
Three new immunologic types of trachoma-inclusion conjunctivitis organisms. J Immunol (1973) 2.96
Prevalence of HIV infection among former commercial plasma donors in rural eastern China. Health Policy Plan (2001) 2.94
A simplified method for immunological typing of trachoma-inclusion conjunctivitis-lymphogranuloma venereum organisms. Infect Immun (1973) 2.93
Correlation of circulating capsular polysaccharide with bacteremia in pneumococcal pneumonia. Infect Immun (1972) 2.93
Escherichia coli invasion of brain microvascular endothelial cells in vitro and in vivo: molecular cloning and characterization of invasion gene ibe10. Infect Immun (1995) 2.91
Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis (1995) 2.90
A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet (1990) 2.89
Characterization of the new Chlamydia agent, TWAR, as a unique organism by restriction endonuclease analysis and DNA-DNA hybridization. J Clin Microbiol (1987) 2.78
Immunotypes of Chlamydia trachomatis isolates in Seattle, Washington. Infect Immun (1983) 2.76
A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumoniae strain TWAR. J Infect Dis (1990) 2.74
Risk factors for delayed immunization in a random sample of 1163 children from Oregon and Washington. Pediatrics (1993) 2.74
Trachoma vaccine studies in monkeys. Am J Ophthalmol (1967) 2.65
Infection of Phaseolus vulgaris by bean golden mosaic virus: ultrastructural aspects. Virology (1978) 2.64
Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA (1992) 2.61
Unique ultrastructure in the elementary body of Chlamydia sp. strain TWAR. J Bacteriol (1987) 2.61
An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis (1985) 2.60
Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. Am J Med (1984) 2.60
Mycoplasma pneumoniae pneumonia in an urban area. Five years of surveillance. JAMA (1970) 2.58
Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (2001) 2.51
Epidemiology of Mycoplasma pneumoniae infection in families. JAMA (1966) 2.49
Detection of Chlamydia pneumoniae by polymerase chain reaction. J Clin Microbiol (1992) 2.49
Relation between sexual practices and T-cell subsets in homosexually active men. Lancet (1983) 2.46
CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 2.45
HIV-1, HIV-2, and HTLV-I infection in high-risk groups in Brazil. N Engl J Med (1989) 2.45
HIV-1 infection in commercial plasma donors in China. Lancet (1995) 2.42
Factors affecting viability and growth in HeLa 229 cells of Chlamydia sp. strain TWAR. J Clin Microbiol (1988) 2.41
Increased frequency of serum antibodies to Chlamydia trachomatis in infertility due to distal tubal disease. Lancet (1982) 2.38
Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol (2001) 2.38
Immunochemical studies on chlamydial group antigen (presence of a 2-keto-3-deoxycarbohydrate as immunodominant group). J Immunol (1972) 2.37
Differentiation of TRIC and LGV organisms based on enhancement of infectivity by DEAE-dextran in cell culture. J Infect Dis (1972) 2.36
Importance of bacterial growth phase in determining minimal bactericidal concentrations of penicillin and methicillin. Antimicrob Agents Chemother (1981) 2.35
Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS (1998) 2.33
Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med (1981) 2.31
Retracted Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature (2000) 2.31
Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am J Epidemiol (1987) 2.29
Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis (2005) 2.28
Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb (1993) 2.27
Three new serovars of Chlamydia trachomatis: Da, Ia, and L2a. J Infect Dis (1991) 2.26
The effects of establishment practices, knowledge and attitudes on condom use among Filipina sex workers. AIDS Care (1998) 2.23
Staphylococcal sphingomyelinase (beta-hemolysin). Ann N Y Acad Sci (1974) 2.22
Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology (1983) 2.22
TRIC type K, a new immunologic type of Chlamydia trachomatis. J Immunol (1974) 2.22
Binding characteristics of S fimbriated Escherichia coli to isolated brain microvascular endothelial cells. Am J Pathol (1994) 2.21
Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res (2007) 2.21
Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis (1983) 2.20
Structure-activity relationships of chemokines. J Leukoc Biol (1995) 2.15
Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol (1999) 2.15
A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol (1997) 2.15